New Retina Radio
06.20.24
Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patients with macular edema. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.
View full description +
Sponsored by Genentech.
Subscribe
11.25.25
Global Discussions in GA: Educating Patients and Encouraging Follow-UpAnat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD
Editorially independent content, supported by Astellas.
11.25.25
Global Discussions in GA: Referral Patterns and Fellow-Eye MonitoringAnat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD
Editorially independent content, supported by Astellas.
11.21.25
Endophthalmitis Rates With and Without Antibiotic ProphylaxisSruthi Arepalli, MD; Jesse Sengillo, MD; and Alexis Warren, MD
11.17.25
The Nuts and Bolts of GA Therapy: Wrapping Up the ConversationCharles Wykoff, MD, PhD; Sruthi Arepalli, MD; and Kenneth Fan, MD, MBA
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
11.13.25
AAO '25: GLP-1s and AMD, and Parity in Retina CareAleksandra Rachitskaya, MD; and Julia Haller, MD
Editorially independent content, supported by Genentech.
11.10.25
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLERahul Khurana, MD; and Arshad Khanani, MD, MA
Editorially independent content, supported by Genentech.
11.06.25
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt DiseasePeter Kaiser, MD; and Michel Michaelides, MD
Editorially independent content, supported by Genentech.
11.03.25
The Nuts and Bolts of GA Therapy: The Discussions ContinueCharles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
Show More